Dentsply Sirona is an American dental equipment manufacturer and dental consumables producer that markets its products in over 120 countries.
| Revenue (TTM) | $3.64B |
| Gross Profit (TTM) | $1.80B |
| EBITDA | $526.00M |
| Operating Margin | 9.24% |
| Return on Equity | -33.00% |
| Return on Assets | 1.96% |
| Revenue/Share (TTM) | $18.24 |
| Book Value | $6.58 |
| Price-to-Book | 1.69 |
| Price-to-Sales (TTM) | 0.62 |
| EV/Revenue | 1.195 |
| EV/EBITDA | 46.81 |
| Quarterly Earnings Growth (YoY) | 15.20% |
| Quarterly Revenue Growth (YoY) | -4.10% |
| Shares Outstanding | $199.35M |
| Float | $187.99M |
| % Insiders | 0.65% |
| % Institutions | 117.77% |
Volatility is currently contracting
Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.
CHARLOTTE, N.C., Sept. 03, 2026 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. (“Dentsply Sirona” or the "Company") (Nasdaq: XRAY) today announced that the Company will participate in the Baird 2026 Global Healthcare Conference. Management is scheduled to present on Tuesday, September 15, 2026, at 11:25 a.m. ET.
"I'll give you 950 billion reasons to buy bonds right now," says Thomas Hayes, who gives a contrarian take on why investors should bolster their portfolios in fixed income. He discusses the "seasonality effect," a crowded AI trade, a complicated geopolitical picture, and a steady rise in crude oil as components he sees leading a lasting bond rally.
New system completes the Surity™ portfolio of external catheters for both men and women Integrates into daily routines to help support management of urinary incontinence at home Designed to operate quietly overnight, new Surity™ System helps minimize nighttime interruptions to support comfort and rest MÖLNDAL, Sweden, Aug. 19, 2026 /PRNewswire/ -- Wellspect HealthCare today announced the U.S. launch of the Surity™ Urinary Management System, a discreet at-home urine collection device designed to support people living with urinary incontinence and those who help care for them. This completes the full Surity™ portfolio in the U.S., following the introduction of the Surity™ Female and Male External Catheters earlier this year.
DENTSPLY SIRONA NASDAQ: XRAY reported second-quarter 2026 revenue of $898 million, down 4.1% on a reported basis and 6.3% on a constant-currency basis, as the dental products company continued its turnaround plan amid lower volumes in several businesses and distributor inventory reductions in Europe.
DENTSPLY SIRONA's Q2 sales fall 4.1% as dental weakness offsets Wellspect growth, while margins improve and 2026 guidance is maintained.
The headline numbers for Dentsply (XRAY) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
XRAY's Q2 results are likely to reflect transformation investments, dealer inventory cuts and weak implants, while Wellspect growth offers support.
Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.
CHARLOTTE, N.C., July 28, 2026 (GLOBE NEWSWIRE) -- Dentsply Sirona, the world's largest diversified manufacturer of professional dental products and technologies, today announced an expansion of its long-standing relationship with Medline Sinclair, one of Canada's leading full-service dental distributors.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on XRAY and any ticker you trade — then tracks every position and per-strategy win rate.
